logo
[breadcrumb_custom]

Tag: IMRN Stock

CROX
Stock

IMRN’s Market Ups and Downs: What’s Behind the 2023 Stock Performance?

The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a gain of 102.67%.However, over the last six months, we can see a weaker performance of 97.40%. Over the last 30 days, the price of IMRN has fallen by 117.13%. And in the last five days, it has surged by 119.65%. Immuron Limited ADR’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $5.96 on 03/07/24 and a low of $1.48 for the same time frame

PNC Stock
Stock

Immuron Limited ADR (IMRN) Stock: A Comprehensive 52-Week Review

Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Immuron Limited ADR’s current trading price is 5.61% away from its 52-week high, while its distance from the 52-week low is 128.90%. The stock’s price range during this period has varied between $1.48 and $3.21. The company, active in the Healthcare sector, saw a trading volume of around 30.31 million for the day, considerably higher average daily volume of 4580.0 observed over the last three months. The market performance of Immuron Limited ADR has been

Trading Signals

On What Basis Did Immuron (IMRN) Stock Rise 21% In Extended Session Friday?

In Friday’s after-hours trading, Immuron Limited (NASDAQ: IMRN) shares increased 21.21% to $2.40 as the pharmaceutical company submitted an application for a new medication. Which document has IMRN filed? This month, Immuron (IMRN) said that it has applied for an investigational new drug (IND) designation for Travelan with the US Food and Drug Administration. Immuron will assess the effectiveness of Travelan’s single-dose regimen in a Phase II clinical study utilizing a controlled human infection model (CHIM) and the enterotoxigenic Escherichia coli (ETEC) strain H10407. Up to 60 healthy adult volunteers are expected to participate in the clinical investigation. Each subject